Pamiparib: all 28 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingNCT06387056Phase 2
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingNCT05526924Phase 1
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingNCT04985721Phase 2
- Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With CancerCompletedNCT03994211Phase 1Results posted
- Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination DeficiencyTerminatedNCT03712930Phase 2Results posted
- Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaCompletedNCT03575065Phase 2Results posted
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Phase 2Results posted
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedNCT03333915Phase 1/2Results posted
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT03150810Phase 1Results posted
- The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsCompletedNCT02660034Phase 1Results posted
- Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance TherapyStatus unknownNCT05669768Phase 2
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
- A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor ExposureActive, not recruitingNCT05489926Phase 2
- Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent ChemoradiotherapyStatus unknownNCT05483543Phase 2
- A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate CancerStatus unknownNCT05376722Phase 2
- Pamiparib in mCRPC With HRD or BRCA1/2 MutationStatus unknownNCT05327621Phase 2
- Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedNCT05038839Phase 1
- Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract CancerWithdrawnNCT04796454Phase 2
- Study of Pamiparib in Newly Diagnosed and rGBMCompletedNCT04614909Early Phase 1
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnNCT04603365Phase 2
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
- Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasActive, not recruitingNCT03749187Phase 1
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingNCT03519230Phase 3
- Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedNCT02361723Phase 1